

Bibliografia

Bibliografia

ECSTASY:

Ajaelo I, Koenig K, Snoey E: Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use [letter] *Acad Emerg Med*, 5:839-840, 1998.

Allen, R.P., McCann, U.D., Ricaurte, G.A. Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. *Sleep* 16(6), pp 560-564 1993.

Battaglia, G., Yeh, S.Y., O'Hearn, E., Molliver, M.E., Kuhar, M.J., DeSouza, E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [³H]paroxetine-labelled serotonin uptake sites. *J Pharmacol Exp Ther*; 242, pp 911-916 1987.

Bolla, KI, McCann, UD., Ricaurte, GA: Memory impairment in abstinent MDMA ("Ecstasy") users. *Neurology* 51(6), pp 1532-1537 1998

Brauer RB, Heidecke CD, Nathrath W, Beckurts K.T, Vorwald P, Zilker TR, Schweigart U, Hölscher AH, Siewert JR: Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. *Transpl Int*, 10:229-233, 1997.

Brodkin, J., Malyala, A., Nash, J.F. Effect of acute monoamine depletion on 3,4-methylene-dioxymethamphetamine-induced neurotoxicity. *Pharmacol. Biochem. Behav.* 45, pp 647-653 1993.

Brody, S., Krause, C., Veit, R., Rau, H. Cardiovascular autonomic dysregulation in users of MDMA ("Ecstasy"). *Psychopharmacology (Berl)* 136, pp 390-393 1998.

Brown C, Osreloh JJ: Multiple severe complications from recreational ingestion of MDMA ("Ecstasy") (letter). *JAMA* 258: 780-781, 1987.

Clark, A.D., Butt, N. Ecstasy-induced very severe aplastic anaemia complicated by invasive pulmonary mucormycosis treated with allogeneic peripheral blood progenitor cell transplant. *Clin Lab Haematol* 19, pp 279-281 1997.

Commins DL, Vosmer G, Virus R, Woolverton W, Schuster C, Seiden L: Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. *J Pharmacol Exp Ther* 241: 338-45, 1987.

Connor, T.J., McNamara, M.G., Finn, D., Currid, A., O'Malley, M., Redmond, A.M., Kelly, J.P., Leonard BE Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. *Immunopharmacology* 38, pp 253-260 1998.

Cooper AJ, Egleston CV: Accidental ingestion of Ecstasy by a toddler: unusual cause for convulsion in a febrile child. *J Accid Emerg Med*, 14:183-184, 1997.

Creighton FJ, Black DL, Hyde CE: "Ecstasy" psychosis and flashbacks. *British Journal of Psychiatry*, 159: 713-715, 1991.

Cunningham M: Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. *Intensive Crit Care Nurs*, 13:216-223, 1997.

Curran HV, Travill RA: Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. *Addiction*, 92:821-831, 1997.

Curran HV, Travill RA: Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. *Addiction*, 92:821-831, 1997.

De Souza, E.B., Battaglia, G., Insel, T.L. Neurotoxic effect of MDMA on brain serotonin neurons: evidence from neurochemical and radioligand binding studies. *Ann. N.Y. Acad. Sci.* 600, pp 682-697 1990.

Demirkiran M, Jankovic J, Dean JM: Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. *Clin Neuropharmacol*, 19: 157-164, 1996.

Dinse, H. [Ecstasy (MDMA) intoxication. An overview]. *Anaesthesist* 46(8), pp 697-703 1997.

Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC: Ecstasy induced hepatitis mimicking viral hepatitis. *Gut*, 36:939-941, 1995.

Eisner, B. Ecstasy: the MDMA Story. Berkeley: Ronin Publishing, 1989

Ellis AJ, Wendon JA, Portmann B, Williams R: Acute liver damage and ecstasy ingestion. *Gut*, 38:454-458, 1996.

Fidler H, Dhillon A, Gertner D, Burroughs A: Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. *J Hepatol*, 25:563-566, 1996.

Fischer, C.A., Hatzidimitriou, G., Katz, J.L., Ricaurte, G.A. Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine. *J Neurosci* 15, pp 5476-5485 1995.

Gerra, G. Ecstasy e metamfetamine: aspetti neuroendocrini e comportamentali. *Atti del Seminario: "Studi sui derivati amfetaminici"* Roma pp. 18-25, 1995.

Gerra, G., Zaimovic, A., Chittolini, B., Giucastro, G., Palladino, M., Gaggiotti, M.T., Caccavari, R. Metilen-dioksi-metamfetamina: aspetti neuroendocrini e comportamentali. *Quaderni Italiani di Psichiatria*, Masson Ed., 3, pp 159-167 1996.

Gerra, G., Zaimovic, A., Giucastro, G., Maestri, M., Monica, C., Sartori, R., Caccavari, R., Delsignore, R. Serotonergic function after ($\pm$) 3, 4-methylenedioxy-methamphetamine (MDMA, "Ecstasy") in humans. *Int Clin Psychopharmacol*, 13, pp 1-9, 1998.

Gerra, G., Zaimovic, A., Giucastro, G., Maestri, M., Monica, C., Sartori, R., Caccavari, R., Delsignore, R. Serotonergic function after ($\pm$) 3, 4-methylenedioxy-methamphetamine (MDMA, "Ecstasy") in humans. *Int Clin Psychopharmacol*, 13, pp 1-9, 1998.

Greer, G., Tolbert, R. Subjective reports of the effects of MDMA in a clinical setting. *J. Psychoactive Drugs* 18, pp 319-327 1986.

Hellinger A, Rauhen U, de Groot H, Erhard J: [Auxiliary liver transplantation for acute liver failure after intake of 3,4-methylenedioxymethamphetamine ("Ecstasy"). *Dtsch Med Wochenschr* 122:716-720, 1997.

Hibell B, Andersson B, Bjarnason T, Kokkevi A, Morgan M, Narusk A: Alcohol and other drug use among students in 26 European Countries. The European School Survey Project on Alcohol and other Drugs, The 1995 ESPAD report, 1996.

Huarte Muniesa MP, Pueyo Royo AM: [Acute hepatitis due to ingestion of Ecstasy] *Rev Esp Enferm Dig*, 87: 681-683, 1995.

Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB: 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. *J Pharmacol Exp Ther* 249: 713-20, 1989.

Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB: 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. *J Pharmacol Exp Ther* 249: 713-20, 1989.

Johnson, M., Sonsalla, P.K., Letter, A.A., Hanson, G.R., Gibb, J.W. Role of the 5-HT₂ receptor in the methamphetamine-induced neurochemical alterations. *J. Pharmacol. Exp. Ther.* 270, pp 97-103 1994.

Khakoo SI, Coles CJ, Armstrong JS, Barry RE: Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. *J Clin Gastroenterol*, 20:244-247, 1995.

McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. *Lancet* 352 (9138): 1433-1437, 1998.

McCann, U.D., Ricaurte, G.A. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. *J. Clin. Psychopharmacol.* 13, pp 214-217 1993.

McCann, U.D., Ridenour, A., Shaham, Y., Ricaurte, G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. *Neuropsychopharmacology* 10, pp 129-138 1994.

McCann, U.D., Slate, S.O., Ricaurte, G.A. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). *Drug Saf* 2, pp 107-115 1996.

Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn EG, Wilson MA: Neurotoxicity of MDMA and related compounds: anatomic studies. *Ann NY Acad Sci* 600: 640-64, 1990.

Morgan, M.J. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. *Neuropsychopharmacology* 19(4), pp 252-264 1998.

Nash JF, Brodtkin J: Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. *J. Pharmacol. Exp. Ther.* 259(2), pp 820-825 1991.

Nichols DE: Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. *J. Psychoactive Drugs* 18, pp 305-313 1986.

Nielsen JC, Nicholson K, Pitzner-Jørgensen BL, Undén M: [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects] *Ugeskr Laeger* 157(6), pp 724-727 1995.

O'Hearn EG, Battaglia G, DeSouza EB, Kuhar MJ, Molliver ME: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. *J Neurosci*; 8: 2788-803, 1988.

Onwudike M: Ecstasy induced retropharyngeal emphysema. *J Accid Emerg Med*, 13:359-361, 1996.

Parr MJ, Low HM, Botterill P: Hyponatraemia and death after "ecstasy" ingestion. *Med J Aust*, 166:136-137, 1997.

Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)* 139(3), pp 261-268 1998.

Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)* 139(3), pp 261-268 1998.

Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)* 139(3), pp 261-268 1998.

Ricaurte GA, Forno LS, Wilson MA, et al.: ($\pm$)3,4-methylenedioxymethamphetamine (MDMA) selectively damages central serotonergic neurons in non-human primates. *JAMA* 260: 51-55, 1988.

Ricaurte, G.A. Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. In: Asghar K, DeSouza E, eds. *Pharmacology and toxicology of amphetamines and related designer drugs*. NIDA Res Monogr 94, pp 306-322 1989.

Ricaurte, G.A., DeLanney, L.E., Irwin, I., Langston, J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. *Brain Res*; 446, pp 165-168 1988.

Ricaurte, G.A., Martello, A.L., Katz, J.L., Martello, M.B. Lasting effects of ($\pm$)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates: neurochemical observations. *J Pharmacol Exp Ther* 261, pp 616-622 1992.

Robinson, T.E., Castaneda, E., Whishaw, I.Q. Effects of cortical serotonin depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. *Neuropsychopharmacology* 8(1), pp 77-85 1993.

Rudnick G, Wall SC: Non- neurotoxic amphetamine derivatives release serotonin through serotonin transporters. *Molecular Pharmacology* 43: 271-276, 1993.

Rudnick G, Wall SC: The molecular mechanism of "ecstasy" (3,4-methylenedioxy-methamphetamine (MDMA)) serotonin transporters are targets for MDMA-induced serotonin release. *Proc. Natl. Acad. Sci. USA*, 89: 1817-1821, 1992.

Scheffel U, Szabo Z, Mathews WB, et al.: In vivo detection of short- and long-term MDMA neurotoxicity: a positron emission tomography study in the living baboon brain. *Synapse* 29: 183-192, 1998.

Scheffel, U., Lever, J.R., Stathis, M., Ricaurte, G.A., Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT₂ receptors. *Neuropharmacology* 31(9), pp 881-893 1992.

Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R: MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. *Drug Alcohol Depend* 52(1), pp 85-90 1998.

Schifano F, Magni G: MDMA ("ecstasy") abuse: psychopathological features and craving for chocolate: a case series. *Biol Psychiatry* 36(11), pp 763-767 1994.

Schifano F: Research on human neurotoxicity of MDMA (ecstasy): subjective self-reports; evidence from a drug addiction centre; clinical case studies. In press, *Neuropsychobiology*, 1998.

Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 240: 1-7, 1987.

Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G: Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. *Molecular Pharmacology* 44: 1227-1231, 1993.

Seymour HR, Gilman D, Quin JD: Severe ketoacidosis complicated by 'ecstasy' ingestion and prolonged exercise. *Diabet Med* 13:908-909, 1996.

Slikker W, Ali SF, Scallet C, Frith CH, Newport GD, Bailey JR: Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). *Toxicol Appl Pharmacol* 94: 448-457, 1988.

Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. *Br. J. Addict*, 87:1161-1172 1992.

Steele TD, McCann UD, Ricaurte GA: 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") pharmacology and toxicology in animals and humans.[Review] *Addiction* 89, pp 539-551 1994.

Thomasius, R., Schmolke, M., Kraus, D. [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae] *Fortschr Neurol Psychiatr* 65(2), pp 49-61 1997.

Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA: Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [¹¹C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. *J Neurosci* 18(1), pp 419-427 1998.

Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A: "Saturday night fever": ecstasy related problems in a London accident and emergency department. *J Accid Emerg Med* 15:322-326, 1998.

Wodarz N, Boning J: "Ecstasy"-induced psychotic depersonalization syndrome. *Nervenarzt*, 64: 478-480, 1993.

CANNABIS:

Emrich HM, Leweke FM, Schneider U Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. *Pharmacol Biochem Behav* 1997 Apr 56:4 803-807.

Tanda G, Pontieri FE, Di Chiara G Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. *Science* 1997;276(5321):2048-2050

COCAINA

Foltin RW, Fischman MW Effects of "binge" use of intravenous cocaine in methadone-maintained individuals. *Addiction* 1998 93:6 825-36.

Haney M, Gerra G, Fischman MW, Foltin RW: Neuroendocrine effects of d-fenfluramine after repeated cocaine self-administration in humans. In press 1999.

Negus SS, Gatch MB, Mello NK Discriminative stimulus effects of a cocaine/heroin "speedball" combination in rhesus monkeys. *J Pharmacol Exp Ther* 1998 285:3 1123-36

Nunes EV, Quitkin FM, Brady R, Stewart JW Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. *Am J Psychiatry* 1991;148(5):667-9

EROINA:

Andersen HS, Sestoft DM, Lillebaek T, Gabrielsen G Heroin abuse among Danish prisoners on remand. II. Consequences related to form of administration]. *ugeskr læger* 1996 158: 4754-4758

Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. *Anesthesiology* 1998;88(1):82-8

Fiorella D, Palumbo PA, Rabin RA, Winter JC The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. *Psychopharmacology (Berl)* 1995;119(2):239-45

Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ Pharmacokinetics and pharmacodynamics of smoked heroin. *J Anal Toxicol* 1994;18(6):317-330.

Marona-Lewicka D, Nichols DE Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. *Psychopharmacology (Berl)* 1995;120(4):384-91

LSD

Altura BT, Altura BM Phencyclidine, lysergic acid diethylamide, and mescaline: cerebral artery spasms and hallucinogenic activity. *Science* 1981;212(4498):1051-2

Batzer W, Ditzler T, Brown C LSD use and flashbacks in alcoholic patients. *J Addict Dis* 1999;18(2):57-63

Hurlbut KM Drug-induced psychoses. *Emerg Med Clin North Am* 1991;9(1):31-52

Leikin JB, Krantz AJ, Zell-Kanter M, Barkin RL, Hryhorczuk DO Clinical features and management of intoxication due to hallucinogenic drugs. *Med Toxicol Adverse Drug Exp* 1989;4(5):324-50

Marona-Lewicka D, Nichols DE Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. *Psychopharmacology (Berl)* 1995;120(4):384-91

Rech RH, Commissaris RL Neurotransmitter basis of the behavioral effects of hallucinogens. *Neurosci Biobehav Rev* 1982;6(4):521-7

Retterstol N Phenothiazine-induced toxic psychosis after LSD. *Can Med Assoc J* 1971;7;105(3):241

Schwartz RH, Smith DE Hallucinogenic mushrooms. *Clin Pediatr (Phila)*. 1988;27(2):70-3.

Selakovic-Bursic S, Bujisic G [The effect of hallucinogenic drugs on the development of psychoses]. *Med Pregl* 1994;47(11-12):421-3

CAPITOLO 7

Able E., Lee JA. Paternal alcohol exposure affects offspring behavior but not body or organ weights in mice. *Alcoholism. Clin. Exp. Res.*, 12: 349-355, 1988.

Bailey SL, Flewelling RL, Rachal JV Predicting continued use of marijuana among adolescents: the relative influence of drug-specific and social context factors. *J Health Soc Behav* 1992;33(1):51-65

Baumann D, Hampich B, Seidlein HJ [Degree of gratification of needs in the use of drugs]. *Pharmazie* 1983;38(1):57-61

Blum K., Sheridan PJ., Wood RC., Braverman ER., Chen TJ., Comings DE. Dopamine D2 receptor gene variants, association and linkage studies in impulsive-addictive-compulsive behaviour. *Pharmacogenetics*, 5: 121-141, 1995.

Boja JW., Kuhar MJ. [³H] cocaine binding and inhibition of [³H] dopamine uptake is similar in both rat striatum and nucleus accumbens. *Eur. J. Pharmacol.*, 173: 215-217, 1989.

Brambilla F., Guareschi-Cazzullo A., Tacchini C., Gerra G., Musetti C. Growth hormone response to growth hormone releasing hormone and to clonidine stimulation in peripubertal patients with major depressive disorder. *Biological Psychiatry*, 36: 51-56, 1994.

Carmelli D., Swan GE., Robinette D., et al. Heritability of substance abuse in the NAS-NRC twin registry. *Acta Genet. Med. Gemellol.*, 39: 91-98, 1990.

Cloninger CR. A systematic method for clinical description and classification of personality variants. *Arch. Gen. Psychiatry*, 44: 573-588, 1987.

Compton P.A., Anglin M.D., Khalsa-Denison M.E., Paredes A. The D2 dopamine receptor gene, addiction, and personality: clinical correlates in cocaine abusers. *Biol. Psychiatr.*, 39: 302-4, 1996.

Devor EJ., Cloninger CR., Hoffman PL., et al., A genetic study of platelet adenylate cyclase activity: Evidence for a single major locus effect in fluoride-stimulated activity. *Am. J. Hum. Gen.*, 49: 372-377, 1991.

Ehlers CL., Schuckit MA. Evaluation of EEG alpha activity in sons of alcoholics. *Neuropsychopharmacology*, 4: 199-205, 1991.

Fadda R., Argiolas A. Melis MR., et al. Differential effect of and chronic ethanol on dopamine metabolism in frontal cortex, caudate nucleus and substantia nigra. *Life Sci.*, 27: 979-986, 1980.

Galanter J., Goldman D., Risch R., et al. The A1 allele at the D2 dopamine receptor gene and alcoholism. *JAMA* 269: 1673-1677, 1993.

Galanter J., Goldman D., Risch R., et al. The A1 allele at the D2 dopamine receptor gene and alcoholism. *JAMA* 269: 1673-1677, 1993.

Galanter M., Egelko S., Edwards H., Vergaray M. A treatment system for combined psychiatric and addictive illness. *Addiction*, 89: 1227-35, 1994.

Galvin M., Shekhar A, Simon J, Stiwell B, Ten Eyck R., Laite G., Karwisch G, Blix S. Low dopamine-β-hydroxylase: a biological sequela of abuse and neglect? *Psychiatry Res.*, 1991: 39: 1-11.

George D.T., Nutt D.J., Dwyer B.A., Linnoila M. Alcoholism and panic disorder: is the comorbidity more than coincidence. *Acta Psych. Scand.*, 81: 97-107, 1990.

Gerra G., Caccavari R., Fontanesi B., Delsignore R., Fertoni-Affini G., Marcato A., Maestri D., Avanzini P., Perna G., Brambilla F., Alpha-2-adrenoceptor sensitivity in heroin addicts with and without previous attention deficit disorder/hyperactivity and conduct disorder. *Neuropsychobiology*, 30: 15-9, 1994.

Gerra G., Ferri M., Zaimovic A., Giucastro G., Palladino M., Sartori R., Chittolini B., Delsignore R., Maestri D., Marzocchi G., Brambilla F. Gabaergic function in detoxified heroin addicts: relationship to anxiety disorders. *Psychiatry Research*, 77:89-96, 1998.

Gerra G., Fertoni G., Tagliavini P., Zaimovic A., Delsignore R., Maestri D., Avanzini P., Caccavari R., Brambilla F., Serotonin function in detoxified heroin abusers: prolactin and cortisol response to the fenfluramine challenge. *Psych. Res.*, 58: 153-160, 1995

Gerra G., Terzi C., Delsignore R., Caccavari R., Gaggiotti MT., Maestri D., Ugolotti G., Chiodera P. and Coiro V. Neuroendocrine responses to physical exercise in adolescents with low self esteem and frustration. *Neuroendocrinol. Lett.*, 13(5): 367-375, 1991.

Gerra G., Volpi R., Delsignore R., Caccavari R., Gaggiotti MT., Montani G., Maninetti L., Chiodera P. and Coiro V. ACTH and beta-endorphin responses to physical exercise in adolescent women tested for anxiety and frustration. *Psychiatry Research*, 41: 179-186, 1992.

Gerra G., Zaimovic A., Chittolini B., Giucastro G., Palladino M., Maestri D., Tessonni A., Avanzini P., Caccavari R., Bernasconi S., Brambilla F. Neurotransmitter - hormonal responses to psychological stress in peripubertal subjects: relationship to aggressive behavior. *Life Sciences*, 62:617-625, 1998.

Gerra G., Zaimovic A., Chittolini B., Giucastro G., Palladino M., Gaggiotti MT., Caccavari R. Metilen-diossi-metamfetamina: aspetti neuroendocrini e comportamentali. *Quaderni di Psichiatria*, 3: 159-167, 1996.

Gerra G., Zaimovic A., Chittolini B., Giucastro G., Palladino M., Gaggiotti MT., Caccavari R. Metilen-diossi-metamfetamina: aspetti neuroendocrini e comportamentali. *Quaderni di Psichiatria*, 3: 159-167, 1996.

Gordon LB Preferential drug abuse: defenses and behavioral correlates. *J Pers Assess* 1980; 44(4):345-50

Handelsman L., Branchey MH., Buydens-Branchey L., Gribomont B., Holloway K., Silverman J. Morbidity risk for alcoholism and drug abuse in relatives of cocaine addicts. *Am. J. Drug. Alcohol Abuse*, 19: 347-357, 1993.

Hesselbrock V., Meyer R., Hesselbrock M. Psychopathology and addictive disorders, in O'Brien CP (ed): *Addictive States*. New York, Raven Press, pp 179-191, 1992.

Imperato A., DiChiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. *J. Pharmacol. Exp. Ther.*, 239: 219-228, 1986.

Khantzian EJ The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. *Harv Rev Psychiatry* 1997;4(5):231-244.

Khatzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. *Am. J. Psychiatry*, 142: 1259-64, 1985.

Kleinman P.H., Miller A.B., Millman R.B., Woody G.E., Todd T., Kemp J., Lipton D.S. Psychopathology among cocaine abusers entering treatment. *J. Nerv. Ment. Dis.*, 178(7): 442-7, 1990.

Leshner A.I. Molecular mechanisms of cocaine addiction. *New England J. of Medicine*, 335: 128-9, 1996.

Limson R., Goldman D., Roy A., et al. Personality and CSF monoamine metabolites in alcoholics and controls. *Arch. Gen. Psychiatry*, 48: 437-441 1991.

Luthar SS., Rounsaville BJ. Substance misuse and comorbid psychopathology in a high risk group: a study of siblings of cocaine misusers. *Int. J. Addict.*, 28: 415-434, 1993.

Merikangas KR. The genetic epidemiology of alcoholism. *Psychol. Med.* 20: 11-22, 1990

Mirin SM., Weiss RD., Griffin ML., Michael JL. Psychopathology in drug abusers and their families. *Compr. Psychiatry*, 32(1): 36-51, 1991.

Moss H., Yao J., Burns M., et al. Plasma GABA-like activity in response to ethanol challenge in men at high risk for alcoholism. *Biol. Psychiatry*, 27: 617-625, 1990.

Pozzi G., Bacigalupi M., Serretti A., Tempesta E. Prevalenza dei disturbi mentali fra gli utenti dei servizi pubblici per le tossicodipendenze in Italia: uno studio multicentrico. *Boll. Farmacodip. e Alcolis.*, XVI (3-4), 1993.

Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. (Review). *Molecular Neurobiology*, 11:1-19, 1995.

Satterfield J.M., Hoppe C.M., Schnell A.M. A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal boys. *Am. J. Psychiatry*, 139: 795-8, 1982.

Schuckit MA., Hauger RL., Monteiro MG., et al. Response of three hormones to diazepam challenge in sons of alcoholics and controls. *Alcoholism. Clin. Exp. Res.*, 12: 537-542, 1991.

Siever, L.J., Kahn, R.S., Lawlor, B.A., Trestman, R.L., Lawrence, T.L. and Coccaro, E.F. Critical issues in defining the role of serotonin in psychiatric disorders. *Pharmacological reviews*, 43: 509-525, 1991.

Tabakoff B., Hoffman PL., Lee JM., et al., Differences in platelet enzyme activities between alcoholics and non-alcoholics. *N. Engl. J. Med.*, 318: 134-139, 1988.

Tanda G, Pontieri FE, Di Chiara G Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. *Science* 1997;276(5321):2048-2050

Von Knorring A., Hallman J., Von Knorring L., et al. Platelet monoamine oxidase activity in type 1 and type 2 alcoholism. *Alcohol Alcoholism.*, 26: 409-416 1991.

Zuckerman M., Kuhlman DM., Camac C. What lies beyond E and N? Factor analyses of scales believed to measure basic dimensions of personality. *J. Pers. Soc. Psychol.*, 54: 96-107, 1988.

CAPITOLO 8

Forsyth AJM, Barnard M, McKeganey NP: Musical preference as an indicator of adolescent drug use. *Addiction*, 1997; 92(10):1317-25

Watson L, Beck J New age seekers: MDMA use as an adjunct to spiritual pursuit. *J Psychoactive Drugs* 1991;23(3):261-70

Andrucci GL, Archer RP, Pancoast DL Gordon RA: The relationship of MMPI and sensation seeking scales to adolescent drug use. *Journal of Personality Assessment*, 1989;53:253-324.

Ariano E, Zucchi A: Epidemiology and territory: what structuring? A local experience in the Lombard region *Epidemiol Prev* 1995;19:250-253.

Ashton CH, Kamali F: Personality, lifestyles, alcohol and drug consumption in a sample of British medical students. *Med Educ* 1995;29:187-192.

Bardo MT, Donohew RL, Harrington NG: Psychobiology of novelty seeking and drug seeking behavior. *Behav Brain Res* 1996;77:23-43.

Chen K, Kandel DB: The natural history of drug use from adolescence to the mid-thirties in a general population sample. *American Journal of Public health* 1995;85:41-47.

Cloninger CR, Sigvardsson S, Bohman M: Childhood personality predicts alcohol abuse in young adults. *Alcoholism: Clinical and Experimental Research* 1988;12:494-505.

Conrod PJ, Petersen JB, Pihl RO: Disinhibited personality and sensitivity to alcohol reinforcement: independent correlates of drinking behavior in sons of alcoholics. *Alcohol Clin Exp Res* 1997;21:7 1320-1332.

Cousineau DF: Relation between illicit drug use and personal problems related to consumption in students; analysis of a self-administered questionnaire *Can J Public Health* 1995;86:2 98-102.

Craig RJ: The personality structure of heroin addicts. National Institute on Drug Abuse Research Monograph Series, Monograph 1986;74:25-36.

Croen LG, Woesner M, Herman M, Reichgott M: A longitudinal study of substance use and abuse in a single class of medical students. Acad Med 1997;72:376-381.

Crum RM, Ensminger ME, Ro MJ, McCord J: The association of educational achievement and school dropout with risk of alcoholism: a twenty-five-year prospective study of inner-city children. J Stud Alcohol 1998;59:3 318-326.

Cuomo MJ, Dymont PG, Gammino VM: Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. J Am Coll Health 1994;42:271-274.

Gerra G., Zaimovic A., Timpano M., Zambelli U., Delsignore R: Aggressiveness and novelty seeking temperament in subjects with a history of substance abuse. In press, 1999.

Hawkins JD, Catalano RF, Miller JY: Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychological Bulletin 1992;112:64-105.

Hibell B, Andersson B, Bjarnason T, Kokkevi A, Morgan M, Narusk A: Alcohol and other drug use among students in 26 European Countries. The European School Survey Project on Alcohol and other Drugs, The 1995 ESPAD report, 1996.

Johnson V, Pandina RJ: A longitudinal examination of the relationships among stress, coping strategies, and problems associated with alcohol use. Alcohol Clin Exp Res 1993;17:696-702.

Labouvie E, Pandina RJ, Johnson V: Developmental trajectories of substance use in adolescence: Differences and predictors. International Journal of Behavioral Development 1991;14:3-5-28.

Lynskey MT, Fergusson DM: Childhood conduct problems, attention deficit behaviors, and adolescent alcohol, tobacco, and illicit drug use. J Abnorm Child Psychol 1995;23:281-302.

Milgram GG: Adolescents, alcohol and aggression. J Stud Alcohol Suppl 1993;11 53-61.

Moorman PP, deCocq van Delwijnen H, van Wessel K, Bauer H: Personality characteristics of drug addicts in the Netherlands (Leiden Psychological Reports LPR-PP02-89). Dept of Psychology, Leiden University, the Netherlands, 1989.

National Household Survey on Drug Abuse 1991-1993

Newcomb MD, Felix-Ortiz M: Multiple protective and risk factors for drug use abuse: Cross-sectional and prospective findings. Journal of Personality and Social Psychology 1992; 63:280-296.

O'Donnell JA, Hawkins JD, Catalano RF, Abbott RD, Day LE: Preventing school failure, drug use, and delinquency among low-income children: Long-term prevention in elementary schools. American Journal of Orthopsychiatry 1995;65:87-100.

Peroutka SJ: Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus *N Engl J Med* 1987;317:24 1542-1543.

Petraitis J, Flay BR: Reviewing theories of adolescent substance use: Organizing pieces in the puzzle. *Psychological Bulletin* 1995;117:67-86.

Poulin C, Elliott D: Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction *CMAJ* 1997;156:1387-1393.

Poulton RG, Brooke M, Moffitt TE, Stanton WR, Silva PA: Prevalence and correlates of cannabis use and dependence in young New Zealanders. *N Z Med J* 1997;110: 68-70.

Rhode P, Lewinsohn PM, Seeley JR: Psychiatric comorbidity with problematic alcohol use in high school students. *Journal of the American Academy of Child and Adolescent Psychiatry* 1996;35:101-109.

Schifano F: Research on human neurotoxicity of MDMA (ecstasy): subjective self-reports; evidence from a drug addiction centre; clinical case studies. In press, *Neuropsychobiology*, 1998.

Schuckit MA: The clinical implication of primary diagnostic groups among alcoholics. *Arch Gen Psychiatry* 1985;42:1043-1049.

Sloboda Z, David SL: Preventing drug use among children and adolescents: A research-based guide *National Institutes of Health pub. No. 97-4212*, 1997.

Tarter RE: Genetics and primary prevention of drug and alcohol abuse. *International Journal of the Addictions* 1995;1479-1484.

Teichman M, Barnea Z, Rahav G: Sensation seeking, state and trait anxiety, and depressive mood in adolescent substance users. *International Journal of the Addictions* 1989;24:87-89.

Webb E, Ashton H, Kelly P, Kamali F: Patterns of alcohol consumption, smoking and illicit drug use in British university students: interfaculty comparisons. *Drug Alcohol Depend* 1997;47:145-153.

Wong CS, Tang CS, Schwarzer R: Psychosocial correlates of substance use: comparing high school students with incarcerated offenders in Hong Kong. *J Drug Educ* 1997;27:147-172.

Bailey SL, Flewelling RL, Rachal JV Predicting continued use of marijuana among adolescents: the relative influence of drug-specific and social context factors. *J Health Soc Behav* 1992;33(1):51-65

Dobkin PL, Charlebois P, Tremblay RE Mother-son interactions in disruptive and nondisruptive adolescent sons of male alcoholics and controls. *J Stud Alcohol* 1997;58(5):546-53

Downs WR, Miller BA Relationships between experiences of parental violence during childhood and women's self-esteem. *Violence Vict* 1998;13(1):63-77

Galvin M., Shekhar A, Simon J, Stiwell B, Ten Eyck R., Laite G., Karwisch G, Blix S. Low dopamine- β -hydroxylase: a biological sequela of abuse and neglect? *Psychiatry Res.*, 39: 1-11, 1991.

Gerra G., Caccavari R., Fontanesi B., Delsignore R., Fertoni AG., Marcato A., Maestri D, Avanzini P., Perna G., Brambilla F. Alpha-2-adrenoreceptors sensitivity in heroin addicts with and without previous attention deficit disorder/ hyperactivity and conduct disorder. *Neuropsychobiology*, 30: 15-19, 1994.

Gerra G., Caccavari R., Marcato A., Zaimovic A., Avanzini P., Monica C., Mutti A., Fontanesi B, Delsignore R., Brambilla F. Alpha-1 and -2 adrenoceptor subsensitivity in siblings of opioid addicts with personality disorders and depression. *Acta Psychiatrica Scandinavica*, 90: 269-273, 1994.

Gerra G., Caccavari R., Zaimovic A., Avanzini P., Chittolini B., Maestri D., Monica C., Fertoni-Affini G., Delsignore R., Brambilla F. Serotonergic Function in mothers of opioid addicts: correlation with comorbid depression. *Acta Scand Psychiatr*, 96: 36-42, 1997.

Gerra G., Calbiani B., Zaimovic A., Sartori R., Ugolotti G., Ippolito L., Delsignore R. Rustichelli P., Fontanesi B. Regional cerebral blood flow in abstinent opioid addicts: correlation with personality traits. *Psychiatry Research* 83:117-126, 1998.

Gerra G., Ferri M., Zaimovic A., Giucastro G., Palladino M., Sartori R., Delsignore R., Maestri D., Marzocchi G., Brambilla F. Gabaergic function in detoxified heroin addicts: relationship to anxiety disorders. *Psychiatry Research*, 77:89-96, 1998.

Gerra G., Fertoni G., Tagliavini P., Zaimovic A., Delsignore R., Maestri D., Avanzini P., Caccavari R. and Brambilla F. Serotonin function in detoxified heroin abusers: prolactin and cortisol responses to fenfluramine challenge. *Psychiatry Research*, 58: 153-160, 1995.

Levin FR, Kleber HD Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. *Harv Rev Psychiatry* 1995;2(5):246-58

Madden GJ, Petry NM, Badger GJ, Bickel WK Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards. *Exp Clin Psychopharmacol* 1997;5(3):256-62

Mannuzza S, Klein RG, Bonagura N, Konig PH, Shenker R Hyperactive boys almost grown up. II. Status of subjects without a mental disorder. *Arch Gen Psychiatry* 1988;45(1):13-8

Indice dei links di maggiore interesse

Indice aggiornato dei links di maggiore interesse presenti su Internet

E' importante sottolineare che la stessa natura della rete Internet non permette un accurato aggiornamento dei siti presenti in quanto questi vengono creati e scompaiono di continuo. E' possibile, tuttavia, affermare che siamo di fronte ad una relativa scarsità di siti dedicati alle tossicodipendenze (almeno paragonando questo campo con altri simili). Sono soprattutto i siti istituzionali che mancano, mentre il numero relativamente basso di siti delle Organizzazioni non professionali potrebbe essere in riferimento con il fatto che chi opera nel settore non ha ancora dimestichezza con questi strumenti.

I siti istituzionali italiani

<http://www.fattifurbo.com>. *Fatti furbo non farti male*. Home page a cura dell'Ufficio del Ministro per la solidarietà sociale dedicato alla recente campagna di prevenzione sulle nuove droghe.

<http://www.affarisociali.it>. Sito del Dipartimento Affari Sociali della Presidenza del Consiglio dei Ministri; contiene una sezione dedicata all'attività dell'ufficio tossicodipendenze.

<http://www.unicri.it/min.san.bollettino>

Sito del Bollettino per le Farmacodipendenze e l'Alcoolismo, a cura dell'Ufficio per la Prevenzione del Ministero della Sanità. Contiene dati ed indicazioni della pubblicazione periodica ed i suoi testi relativi agli ultimi anni.

Siti non italiani

Il panorama è molto vasto e composito. Si preferisce fare riferimento ai due siti statunitensi di maggiore prestigio e a due siti europei. Da questi si possono raggiungere molti altri siti correlati:

<http://www.nida.nih.gov> Il sito del National Institute of Drug Abuse. Si tratta dell'Agenzia governativa che si occupa da molto tempo delle ricerche e dell'informazione nel settore delle tossicodipendenze, dell'intervento e della prevenzione.

<http://www.health.org/ncda/> Il sito della National Clearing house sull'abuso di alcool e di droghe: ricco di informazioni e di links.

<http://www.frw.uva.nl/acd/isg/drugs/> Il sito del Centro Ricerche dell'Università di Amsterdam dedicato alle droghe ed alle ricerche settoriali.

<http://www.itaca-europe.org> Il sito di Itaca Europa, l'Associazione Europea degli Operatori Professionali delle Tossicodipendenze che si occupa dell'aspetto relativo all'intervento.

Siti di Servizi Pubblici

<http://www.ausl5.la-spezia.it/droga/index.htm> Il sito del SerT AUSL 5 di La Spezia dal titolo: "Le dipendenze. Conoscere e capire la droga". Un panorama di facile lettura sul mondo della tossicodipendenza.

<http://www.tin.it/anriucsc/anri> Il Centro antiveleni del Policlinico Gemelli (Roma) fornisce un servizio di domande anonime e risposte pubbliche su questioni tossicologiche generali:

<http://www.apf.cbft.unipd.it/> Sito del Centro di Tossicologia Forense dell'Università di Padova.

<http://194.179.159.10/web/intsert.nsf/pages/HomePage> Il sito del Servizio Dipendenze (SerT) di Bergamo. Contiene informazioni sull' European Collaborating Centres in Addiction Studies .

Siti del Privato Sociale

<http://www.sapienza.it/html-doc/fermo/assoc/cnca.htm> Il Sito del Coordinamento Nazionale delle Comunità di Accoglienza:

<http://www.ceis.it> Il sito del Centro Italiano di Solidarietà

<http://www.exodus.it> Il sito di Exodus. Contiene anche un servizio di documentazione:

<http://www.fict.it> Il sito della Federazione Italiana delle Comunità Terapeutiche

<http://www.fcn.net/maraini> il sito della Fondazione Villa Maraini:

<http://services.csi.it/~abele/gruppo.htm> Il sito del Gruppo Abele:

Siti Internet di Associazioni

<http://www.uni.net/federsert> Il sito della Federazione degli operatori dei SerT-FederSerT:

<http://www.freeweb.org/associazioni/fedsertsicilia>

<http://www.mclink.it/assoc/itaca-italia> Il sito della delegazione italiana di Itaca:

<http://www.erit.org/indexit.html> Il sito della Federazione Europea delle Associazioni degli Operatori delle Tossicodipendenze-Erit:

<http://versilia.toscana.it/pietrasanta/sims.html> Il sito del "Gruppo di Pietrasanta"

<http://vol.it/it/scienza/medicina/poliscienze/cov-meds.htm> Il sito della rivista "Medicina delle Tossicodipendenze"

<http://www.citinv.it/associazioni/SIMS/sims.htm> il sito del "Gruppo Sims-Studio e Intervento sulle Malattie Sociali ":

<http://www.publinet.it/pol/ital/tossicod.htm> Il sito di POLIT, la sezione sulle tossicodipendenze di Psichiatria on Line Italiana:

Altri siti di particolare interesse

<http://ourworld.compuserve.com/homepages/Gatti/> Il sito Internet di Riccardo C. Gatti. Molto aggiornato ed interessante, è stata la base per identificare i siti citati in questo aggiornamento.

<http://www.crest.it> il sito del Crest, il Centro per lo studio e la cura dei disturbi di personalità e di tossicodipendenza:

<http://www.aspide.it/freeweb/DSA> il sito di: DisSerTAzioni-esperienze di intervento sociale, psicologico e psicoterapeutico nei SerT:

<http://psychomedia.it/pm/answer/addindx1.htm> Il sito di Psychomedia - risposta al disagio- Dipendenze e Nuove Dipendenze:

<http://www.vita.it> Il sito di: Vita -Settimanale del volontariato e del non profit.. Dedica molto spazio al problema delle tossicodipendenze:

<http://www.iefcos.it/valuta> Il sito del progetto Cost A6 Italia, dedicato al problema della valutazione nel campo dell'intervento preventivo e del trattamento delle tossicodipendenze:

<http://www.agora.stm.it/coronet> Il sito del Coordinamento Radicale Antiproibizionista

<http://www.aenne.it/droga/inddrog.htm> Il sito di Alleanza Nazionale dedicato al problema della lotta alla droga: